Lin Xinyu, Ren Shuling, Li Tingdong, Ge Shengxiang
National Institute of Diagnostics and Vaccine Development in Infectious Diseases (Xiamen University), Xiamen 361102, Fujian, China.
Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen 361102, Fujian, China.
Sheng Wu Gong Cheng Xue Bao. 2025 Apr 25;41(4):1268-1279. doi: 10.13345/j.cjb.240425.
With the continuous development of messenger RNA (mRNA) technology, mRNA-based drugs have shown broad application prospects in recent years. Since mRNA is easy to be degraded and difficult to enter cells directly, the mRNA delivery vectors have always been one of the focuses in the development of mRNA-based drugs. Although lipid nanoparticles (LNPs) have been widely used for the delivery of mRNA, they tend to accumulate in the liver, and repeated administration can easily induce inflammatory response which leads to tissue damage. Compared with LNPs, virus-like particles (VLPs) have the advantages of high biocompatibility and safety, being expected to offer new solutions for mRNA delivery. Based on the practical application requirements, this review summarized the research progress in VLPs according to the mRNA delivery steps: particle assembly, delivery into cells, and intracellular release. We hope to provide a basis and design ideas for the development of new VLPs as delivery vectors, promote the application of VLPs in mRNA delivery, and provide new possibilities for the research and application of mRNA-based therapeutics.
随着信使核糖核酸(mRNA)技术的不断发展,近年来基于mRNA的药物展现出广阔的应用前景。由于mRNA易于降解且难以直接进入细胞,mRNA递送载体一直是基于mRNA的药物研发的重点之一。尽管脂质纳米颗粒(LNPs)已被广泛用于mRNA递送,但它们倾向于在肝脏中蓄积,且重复给药容易引发炎症反应,导致组织损伤。与LNPs相比,病毒样颗粒(VLPs)具有高生物相容性和安全性的优点,有望为mRNA递送提供新的解决方案。基于实际应用需求,本综述根据mRNA递送步骤(颗粒组装、递送至细胞和细胞内释放)总结了VLPs的研究进展。我们希望为开发新型VLPs作为递送载体提供依据和设计思路,促进VLPs在mRNA递送中的应用,并为基于mRNA的治疗方法的研究和应用提供新的可能性。